Clinical trials: Skin Toxicity
Breast Cancer
Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy
This study is a single-centered, double-blind, two-arm randomized study to determine if oral glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving Therapy.
- Trial name
- NCT02012608
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Arkansas
Early Breast Cancer, Skin Condition
An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)
The goal of this European observational study (Frane, Spain, italy, Spain and Greece) is to describe the quality of life related to dermatological toxicities, in adult women patients with Early Breast Cancer (EBC), treated with…
- Conditions
- Early Breast Cancer, Skin Condition, Quality of Life
- Trial name
- BCARE (NCT06690489)
- Where
- 9 sites in France, Greece and 2 more
- Volunteers
- 155 people
- Sponsor
- Pierre Fabre Medicament
Breast Cancer
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating older women who have stage IV…
- Trial name
- NCT00022152
- Testing
- vinorelbine tartrate
- Where
- 18 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Chemotherapeutic Agent Toxicity
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
RATIONALE: L-carnitine L-tartrate may prevent peripheral neuropathy caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well L-carnitine L-tartrate works in preventing peripheral neuropathy caused by…
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neurotoxicity
- Trial name
- NCT00754767
- Testing
- L-carnitine L-tartrate
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- HealthPartners Institute
Head and Neck Cancer, Lung Cancer
Subcutaneous Amifostine Safety Study
Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously.
- Conditions
- Head and Neck Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT00158041
- Testing
- Amifostine administered subcutaneously
- Where
- United States
- Volunteers
- 452 people
- Sponsor
- Mt. Sinai Medical Center, Miami
Hand Foot Skin Syndrome
Topical Cosmetic Products for Hand and Foot Syndrome
The aim of the study is to evaluate the efficacy of a dermocosmetic protocol in reducing the main cutaneous side effects that occur in palmar-plantar erythrodysesthesia syndrome in subjects with a tumor diagnosis, undergoing…
- Trial name
- NCT06586073
- Testing
- cosmetic products
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Dermophisiologique s.r.l
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
Nutritional and Metabolic Management of Toxidermia Patients Requiring Intensive Care (TEN Metabolism)
Retrospective observational cohort study including all patients admitted for toxidermia (Lyell syndrome, Stevens-Johnson Syndrome (SJS), or other extensive skin destruction) to the Burn unit of the adult ICU of the Lausanne burn…
- Trial name
- TEN metabolism (NCT05320653)
- Testing
- Medical nutrition
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
The goal of this study is to evaluate the effect of tofacitinib in patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The primary outcome of the study is the time to complete re-epithelialization.
- Trial name
- NCT06474078
- Testing
- Tofacitinib
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer, Breast Cancer
Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients.
- Trial name
- NCT06765252
- Testing
- Capecitabine-based chemotherapy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Triple Negative Breast Cancer (TNBC)
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)
This study aims to collect information about the effects of chemotherapy combined with immunotherapy (immune checkpoint inhibitors) for early-stage triple-negative breast cancer (TNBC) on ovarian function and fertility.
- Trial name
- FERTILE (NCT07527819)
- Where
- 9 sites in Australia
- Volunteers
- 75 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer, Colon Cancer
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Background: The p53 gene normally helps to stop cancer cells from growing. However, when the p53 gene is mutated or damaged, cancer cells may grow unchecked.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma
- Trial name
- NCT01386502
- Testing
- p53: 264-272 peptide, CT-011
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Oral Cancer Directed Therapy, Breast Cancer
EHR-embedded OCDT in Breast or GI Cancer
This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy).
- Conditions
- Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
- Trial name
- NCT03858712
- Testing
- Active Care Team Alert, Passive Care Team Alert
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
The purpose of this study is to determine if the dose of radiation therapy that is effective in producing a treatment response, delivered over a shorter treatment period, is a safe approach that causes few or mild side effects in…
- Conditions
- Invasive Ductal Breast Carcinoma, Invasive Ductal Carcinoma, Breast, DCIS, DCIS Grade 1
- Trial name
- NCT04084730
- Testing
- Accelerated Partial Breast Irradiation
- Where
- 9 sites in United States
- Volunteers
- 280 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Carcinoma
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
Skin toxicity treatment in patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS treated with panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and…
- Trial name
- NCT01418742
- Testing
- Panitumumab
- Where
- 12 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Cancer
Prevention of Capecitabine Induced Hand and Foot Syndrome
Capecitabine is a common anti cancer drug. One of the most common side effects is a syndrome called hand and foot syndrome which comprises of hands and feet redness, swelling, dryness and painful sores.
- Trial name
- NCT01291628
- Testing
- socks containing copper-oxide fibers
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Rabin Medical Center
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00296036
- Testing
- pyridoxine hydrochloride, urea/lactic acid-based topical cream
- Where
- 231 sites in United States
- Volunteers
- 137 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Radiation Toxicity
Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT
The goal of this interventional study is to evaluate the risk of atrial fibrillation (AF) and other cardiac arrhythmias and diseases in breast cancer patients treated with radiation therapy (RT).
- Conditions
- Breast Cancer, Radiation Toxicity, Atrial Fibrillation, Cardiac Arrhythmia
- Trial name
- WATCH (NCT06073509)
- Testing
- Screening for atrial fibrillation and other cardiac arrhythmias and diseases
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Sophie JACOB
Breast Cancer, Glioma
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of predictive tests to avoid…
- Conditions
- Breast Cancer, Glioma, Prostate Cancer, Carcinoma, Squamous Cell
- Trial name
- NCT00122239
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer
APBI: 27Gy in 5 Fractions for Early Breast Cancer
This study will test the safety of partial breast RT using 27Gy in 5 daily fractions which is expected to be equally tolerated as standard whole breast irradiation (WBI) based on radiobiologic modeling of the fibrosis response of…
- Trial name
- ACCEL (NCT02681107)
- Testing
- APBI 27Gy in 5 fractions
- Where
- Canada
- Volunteers
- 274 people
- Sponsor
- AHS Cancer Control Alberta